Abstract
Background
Large cell transformation (LCT) of Sezary Syndrome (SS) is a rare phenomenon. To date, there are no rigorous studies identifying risk factors for its development.
Objectives
Here, we seek to characterize the clinicopathologic risk factors that predispose patients with SS to develop LCT.
Methods
We retrospectively evaluated all SS patient records available in the Michigan Medicine Cancer Registry from 2010–2021. Clinical and pathologic variables were compared between groups. The Kaplan-Meier method and log-rank test were used to assess overall survival.
Results
Of 28 SS patients identified, eight patients experienced LCT, and 20 did not (NLCT). Peak lactate dehydrogenase (LDH) before LCT (p = 0.0012), maximum total body surface area (TBSA) involvement before LCT (p = 0.0114), absolute CD8+ cell count measured on flow cytometry at diagnosis of SS (p = 0.0455) and at the most recent blood draw (p = 0.00736), and ulceration on biopsy (p = 0.0034) were significant clinicopathologic variables identified between the SS patients that developed LCT versus those that did not.
Conclusions
Maximum TBSA involvement, peak LDH, presence of ulceration, and decreased levels of CD8+ cells in the peripheral blood may predict the development of LCT in patients with SS.
Funder
Foundation for the National Institutes of Health
Dermatology Foundation
National Psoriasis Foundation
Publisher
Public Library of Science (PLoS)